Amgen Defeats Challenge To European Heart Drug Patent
Amgen and fellow biotech company Cytokinetics fought off a second attack on a potential new treatment for heart failure, as European patent officials ruled that the benefits of a specific salt...To view the full article, register now.
Already a subscriber? Click here to view full article